1216222-91-1

Basic information

• Product Name: IMidazo[1,2-a]pyridine, 6-broMo-3-Methyl-
• Synonyms: IMidazo[1,2-a]pyridine, 6-broMo-3-Methyl-;6-bromo-3-methylimidazo[1,2-a]pyridine
• CAS NO: 1216222-91-1
• Molecular Formula: C8H7BrN2
• Molecular Weight: 211.05858
• Mol File: 1216222-91-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.60±0.1 g/cm3(Predicted)
• PKA: 5.63±0.50(Predicted)
• CAS DataBase Reference: IMidazo[1,2-a]pyridine, 6-broMo-3-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine, 6-broMo-3-Methyl-(1216222-91-1)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine, 6-broMo-3-Methyl-(1216222-91-1)

Safety Data

• Hazardous Substances Data: 1216222-91-1(Hazardous Substances Data)

Usage

Uses

6-bromo-3-methylimidazo[1,2-a]pyridine is a useful chemical reagent.

Upstream product

• 1448263-43-1 tert-butyl 5-bromopyridin-2-yl(prop-2-ynyl)carbamate 
• 159451-66-8 tert-butyl N-(5-bromopyridin-2-yl)carbamate 
• 1249043-95-5 5-bromo-N-(prop-2-ynyl)pyridine-2-amine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 19967-57-8 bromo-2 propanal 
• 33170-72-8 2-bromo-1,1-dimethoxypropane 
• 683-50-1 2-chloropropanal 
• 3400-55-3 2-bromopropionaldehyde diethyl acetal 

Relevant articles and documents

INHIBITORS OF LIN28 AND METHODS OF USE THEREOF

The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cancers.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.